Search results for "Life Sciences & Biomedicine"

showing 10 items of 253 documents

Predicting Lung Deposition of Extrafine Inhaled Corticosteroid-Containing Fixed Combinations in Patients with Chronic Obstructive Pulmonary Disease U…

2021

Background: Functional respiratory imaging (FRI) is a computational fluid dynamics-based technique using three-dimensional models of human lungs and formulation profiles to simulate aerosol deposition. Methods: FRI was used to evaluate lung deposition of extrafine beclomethasone dipropionate (BDP)/formoterol fumarate (FF)/glycopyrronium bromide (GB) and extrafine BDP/FF delivered through pressurized metered dose inhalers and to compare results with reference gamma scintigraphy data. FRI combined high-resolution computed tomography scans of 20 patients with moderate-to-severe chronic obstructive pulmonary disease (mean forced expiratory volume in 1 second 42% predicted) with in silico comput…

PathologyRespiratory SystemPharmaceutical ScienceINHALATION030226 pharmacology & pharmacyPulmonary Disease Chronic Obstructive0302 clinical medicineAdrenal Cortex HormonesFormoterol FumaratePharmacology (medical)1102 Cardiorespiratory Medicine and Haematologycombination drugLungBRONCHODILATOROriginal Researchlung depositionBeclomethasonerespiratory systemDrug CombinationsTreatment OutcomeCorticosteroid1115 Pharmacology and Pharmaceutical SciencesPMDILife Sciences & BiomedicineCombination drugPulmonary and Respiratory Medicinemedicine.medical_specialtyLung depositionextrafinemedicine.drug_classIn silicoPulmonary diseaseSettore MED/10 - Malattie Dell'Apparato Respiratorioinhaled corticosteroid03 medical and health sciencespressurized metered-dose inhalerAdministration InhalationmedicineHumansIn patientComputer SimulationSMALL AIRWAYScombination drug extrafine functional respiratory imaging inhaled corticosteroid lung deposition pressurized metered-dose inhalerScience & TechnologyRespiratory imagingbusiness.industryDYSFUNCTION030228 respiratory systemASTHMAfunctional respiratory imagingbusiness
researchProduct

Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980-2015 : a systematic analysi…

2016

BACKGROUND: Established in 2000, Millennium Development Goal 4 (MDG4) catalysed extraordinary political, financial, and social commitments to reduce under-5 mortality by two-thirds between 1990 and 2015. At the country level, the pace of progress in improving child survival has varied markedly, highlighting a crucial need to further examine potential drivers of accelerated or slowed decreases in child mortality. The Global Burden of Disease 2015 Study (GBD 2015) provides an analytical framework to comprehensively assess these trends for under-5 mortality, age-specific and cause-specific mortality among children under 5 years, and stillbirths by geography over time. METHODS: Drawing from ana…

PediatricsNutrition and DiseaseGlobal HealthCommunicable Disease0302 clinical medicineVoeding en ZiekteInfant MortalityCompensation law of mortalityGlobal healthMedicineLIFE EXPECTANCY030212 general & internal medicineDEVELOPING-COUNTRIES10. No inequalityMedicine(all)NEWBORN BABIESMedicine (all)Mortality rate1. No povertyDEATHPublic Health Global Health Social Medicine and EpidemiologyGeneral Medicine11 Medical And Health SciencesStillbirth3. Good healthChild MortalitySURVIVALCHILD-MORTALITYHEALTHLife Sciences & BiomedicineDEVELOPMENT GOAL 4HumanINTERVENTIONSmedicine.medical_specialtyRJINTEGRATED APPROACHDeveloping country610Communicable Diseasesneonatal03 medical and health sciencesMedicine General & Internal030225 pediatricsGeneral & Internal MedicineLife ScienceHumansGlobal Burden of Disease StudyVLAGEstimationScience & Technologybusiness.industryKlinisk medicinInfantGBD 2015 Child Mortality CollaboratorsInfant mortalityMalariaChild mortalityFolkhälsovetenskap global hälsa socialmedicin och epidemiologiLife expectancyClinical MedicineRGbusinessDemography
researchProduct

Expertise

2017

Several sets of guidelines have been published recently and more are in the works. The very recent American College of Physicians/American Academy of Family Practitioners guidelines were put together by a set of authors and consultants without any expertise in the topic under discussion, that is, hypertension. Although we are not maintaining that all guidelines should be written exclusively by experts, complete lack of expertise among guideline authors is not acceptable. ispartof: Journal Of Hypertension vol:35 issue:8 pages:1564-1566 ispartof: location:Netherlands status: published

Pediatricsmedicine.medical_specialtyhypertensionPhysiologySine qua nonAlternative medicineMEDLINE030204 cardiovascular system & hematology1102 Cardiovascular Medicine And Haematology03 medical and health sciencesProfessional Competence0302 clinical medicineInternal MedicinemedicineHumansBLOOD-PRESSURE TARGETSguidelines030212 general & internal medicineSet (psychology)Societies MedicalMETAANALYSISANGIO-EDEMAOLDERMedical educationScience & Technologybusiness.industry1103 Clinical SciencesAGED 60 YEARSGuidelineProfessional competence3. Good healthPeripheral Vascular DiseaseCardiovascular System & HematologyPractice Guidelines as TopicCardiovascular System & CardiologyexpertiseINHIBITORSCardiology and Cardiovascular MedicinebusinessLife Sciences & BiomedicineguidelineANGIO-EDEMAJournal of Hypertension
researchProduct

Formulation predictive dissolution (fPD) testing to advance oral drug product development: an introduction to the US FDA funded ‘21st Century BA/BE’ …

2018

Over the past decade, formulation predictive dissolution (fPD) testing has gained increasing attention. Another mindset is pushed forward where scientists in our field are more confident to explore the in vivo behavior of an oral drug product by performing predictive in vitro dissolution studies. Similarly, there is an increasing interest in the application of modern computational fluid dynamics (CFD) frameworks and high-performance computing platforms to study the local processes underlying absorption within the gastrointestinal (GI) tract. In that way, CFD and computing platforms both can inform future PBPK-based in silico frameworks and determine the GI-motility-driven hydrodynamic impac…

Physiologically based pharmacokinetic modellingBioavailabilityComputer scienceManometryDrug CompoundingAdministration OralPharmaceutical Science02 engineering and technologyBioequivalenceComputational fluid dynamics030226 pharmacology & pharmacyArticleDOSAGE FORMSINDUCED VARIABILITY03 medical and health sciences0302 clinical medicineBIOPHARMACEUTICS CLASSIFICATION-SYSTEMABSORPTIONHumansDissolution testingOral absorptionPharmacology & PharmacyDissolutionIN-VIVO DISSOLUTIONIn vivo dissolutionBioequivalenceScience & TechnologyWORKSHOP REPORTUnited States Food and Drug Administrationbusiness.industryGASTROINTESTINAL SIMULATOR GISVITRO DISSOLUTION021001 nanoscience & nanotechnologyBiopharmaceutics Classification SystemUnited StatesMODELDrug LiberationNew product developmentPredictive powerDIFFUSION-CONTROLLED DISSOLUTIONBiochemical engineering0210 nano-technologybusinessLife Sciences & BiomedicineOral retinoidMRI
researchProduct

In vitro models for the prediction of in vivo performance of oral dosage forms: Recent progress from partnership through the IMI OrBiTo collaboration

2019

The availability of in vitro tools that are constructed on the basis of a detailed knowledge of key aspects of gastrointestinal (GI) physiology and their impact on formulation performance and subsequent drug release behaviour is fundamental to the success and efficiency of oral drug product development. Over the last six years, the development and optimization of improved, biorelevant in vitro tools has been a cornerstone of the IMI OrBiTo (Oral Biopharmaceutics Tools) project. By bringing together key industry and academic partners, and by linking tool development and optimization to human studies to understand behaviour at the formulation/GI tract interface, the collaboration has enabled …

Process managementUPPER GASTROINTESTINAL-TRACTAdministration OralPharmaceutical Science02 engineering and technologyWATER DIFFUSIVITYModels Biological030226 pharmacology & pharmacyDosage formBiopharmaceutics03 medical and health sciences0302 clinical medicineDISINTEGRATION TESTERHumansPharmacology & PharmacyWEAK BASESIntersectoral CollaborationBiologyTEST DEVICEDosage FormsALBENDAZOLE CONCENTRATIONSScience & TechnologyHuman studiesbusiness.industryBiopharmaceuticsFED STATE CONDITIONSGeneral Medicine021001 nanoscience & nanotechnologyRELEASE TABLETSGastrointestinal TractPharmaceutical PreparationsGastrointestinal AbsorptionGeneral partnershipSOLID DISPERSIONNew product developmentDrug releaseIntersectoral Collaboration0210 nano-technologybusinessLife Sciences & BiomedicineUPPER SMALL-INTESTINEOral retinoidForecastingBiotechnology
researchProduct

Catalyzing transcriptomics research in cardiovascular disease: The CardioRNA COST action CA17129

2019

WOS: 000474931400001

Project Report0301 basic medicinemedicine.medical_specialtyBiochemistry & Molecular BiologyKnowledge managementlcsh:QH426-470BIOMARKERSbest practices and guidelines; cardiovascular disease; personalized medicine; transcriptomics; translational researchContext (language use)Translational researchDisease030204 cardiovascular system & hematologyBiologyBiochemistryLONG NONCODING RNAS03 medical and health sciencestranscriptomics0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemCIRCULATING MICRORNASTARGETScardiovascular diseaseGeneticsmedicineCost actionSet (psychology)Molecular BiologyComputingMilieux_MISCELLANEOUSGenetics & HeredityScience & Technologybusiness.industryCardiovascular system -- DiseasesPublic healthMedicine -- Research -- International cooperationpersonalized medicine3. Good healthlcsh:Genetics030104 developmental biologyAction (philosophy)PERSPECTIVEStranslational researchPersonalized medicineTranslational research biomedicalbest practices and guidelinesbusinessTranscriptomeLife Sciences & Biomedicine
researchProduct

Online consultations in mental healthcare: Modelling determinants of use and experience based on an international survey study at the onset of the pa…

2022

INTRODUCTION: While online consultations have shown promise to be a means for the effective delivery of high-quality mental healthcare and the first implementations of these digital therapeutic contacts go back nearly two decades, uptake has remained limited over the years. The onset of the COVID-19 pandemic dramatically altered this relative standstill and created a unique turning point, with a massive amount of both professionals and clients having first hands-on experiences with technology in mental healthcare. OBJECTIVE: The current study aimed to document the uptake of online consultations and explore if specific characteristics of mental health professionals across and beyond Europe c…

PsychiatryScience & TechnologyPsychology ClinicalSocial SciencesCOVID-19Health InformaticsDigital mental healthdigital mental health ; COVID-19 ; online consultations ; telepresenceTELEPSYCHOLOGYCLINICSHealth Care Sciences & ServicesCOVID-19; Digital mental health; Online consultations; Telepresence;TelepresenceSettore M-PSI/08 - Psicologia Clinica[SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental healthPSYCHOTHERAPYPsychologyLife Sciences & BiomedicineMedical InformaticsOnline consultations
researchProduct

Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018

2021

Anemia is a globally widespread condition in women and is associated with reduced economic productivity and increased mortality worldwide. Here we map annual 2000–2018 geospatial estimates of anemia prevalence in women of reproductive age (15–49 years) across 82 low- and middle-income countries (LMICs), stratify anemia by severity and aggregate results to policy-relevant administrative and national levels. Additionally, we provide subnational disparity analyses to provide a comprehensive overview of anemia prevalence inequalities within these countries and predict progress toward the World Health Organization’s Global Nutrition Target (WHO GNT) to reduce anemia by half by 2030. Our results …

Psychological interventionDiseasesResearch & Experimental MedicineGlobal HealthPrevalence11 Medical and Health Sciencesmedia_commonCHILD GROWTH FAILUREPublic Health Global Health Social Medicine and EpidemiologyAnemiaGeneral MedicineMiddle AgedanemiaPeer reviewIRON-DEFICIENCYNutritional StatuPREGNANCYMedicine Research & ExperimentalScale (social sciences)reproductive age/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingA990 Medicine and Dentistry not elsewhere classifiedFemalewomenLife Sciences & Biomedicinevulnerable populationsHumanAdultmedicine.medical_specialtyBiochemistry & Molecular BiologyInequalityAdolescentAnemiamedia_common.quotation_subjectMODELSImmunologyNutritional StatusReproductive ageLocal Burden of Disease Anaemia CollaboratorsGeneral Biochemistry Genetics and Molecular BiologyDeveloping CountrieYoung AdultSDG 3 - Good Health and Well-beingEnvironmental healthmedicineLife ScienceHumansDeveloping CountriesPovertyGlobal NutritionPregnancyWereldvoedingScience & Technologybusiness.industryPublic healthCell BiologyGLOBAL BURDENmedicine.diseaseFolkhälsovetenskap global hälsa socialmedicin och epidemiologiRisk factors1182 Biochemistry cell and molecular biology3111 Biomedicinebusiness
researchProduct

A model for estimating the health economic impact of earlier diagnosis of chronic thromboembolic pulmonary hypertension

2021

Background Diagnostic delay of chronic thromboembolic pulmonary hypertension (CTEPH) exceeds 1 year, contributing to higher mortality. Health economic consequences of late CTEPH diagnosis are unknown. We aimed to develop a model for quantifying the impact of diagnosing CTEPH earlier on survival, quality-adjusted life-years (QALYs) and healthcare costs. Material and methods A Markov model was developed to estimate lifelong outcomes, depending on the degree of delay. Data on survival and quality of life were obtained from published literature. Hospital costs were assessed from patient records (n=498) at the Amsterdam UMC – VUmc, which is a Dutch CTEPH referral center. Medication costs were ba…

Pulmonary and Respiratory Medicine7medicine.medical_specialtyRespiratory SystemImproved survival610 Medicine & healthQuality of lifeQUALITY-OF-LIFEOriginal Research ArticlesHealth caremedicineEconomic impact analysisIntensive care medicineANGIOPLASTYEconomic consequencesDisease burdenPulmonary Vascular DiseaseScience & Technologybusiness.industry10031 Clinic for AngiologyR2740 Pulmonary and Respiratory MedicineReferral centerMedicineChronic thromboembolic pulmonary hypertensionbusinessLife Sciences & Biomedicine
researchProduct

The disease-specific clinical trial network for primary ciliary dyskinesia: PCD-CTN

2022

Primary ciliary dyskinesia; Rare genetic disorder; Lung diseases Discinesia ciliar primaria; Trastorno genético raro; Enfermedades pulmonares Discinesia ciliar primària; Trastorn genètic rar; Malalties pulmonars Primary ciliary dyskinesia (PCD) is a rare genetic disorder characterised by impaired mucociliary clearance leading to irreversible lung damage. In contrast to other rare lung diseases like cystic fibrosis (CF), there are only few clinical trials and limited evidence-based treatments. Management is mainly based on expert opinions and treatment is challenging due to a wide range of clinical manifestations and disease severity. To improve clinical and translational research and facili…

Pulmonary and Respiratory Medicine:enfermedades respiratorias::trastornos de la motilidad ciliar [ENFERMEDADES]:Health Occupations::Medicine::Pediatrics [DISCIPLINES AND OCCUPATIONS]Respiratory SystemSağlık BilimleriClinical Medicine (MED)SOLUNUM SİSTEMİRespiratory CareHealth SciencesMANAGEMENTKlinik Tıp (MED)Chest Diseases and Allergy:profesiones sanitarias::medicina::pediatría [DISCIPLINAS Y OCUPACIONES]:Otros calificadores::/terapia [Otros calificadores]:Respiratory Tract Diseases::Ciliary Motility Disorders [DISEASES]Internal Medicine SciencesScience & TechnologyKlinik TıpMUTATIONSRESPIRATORY SYSTEM:Other subheadings::/therapy [Other subheadings]Dahili Tıp BilimleriGöğüs Hastalıkları ve AllerjiCLINICAL MEDICINECèl·lules - Motilitat:Congenital Hereditary and Neonatal Diseases and Abnormalities::Genetic Diseases Inborn [DISEASES]TıpPulmons - Malalties - TractamentAkciğer ve Solunum TıbbıMedicineMalalties congènites:enfermedades y anomalías neonatales congénitas y hereditarias::enfermedades genéticas congénitas [ENFERMEDADES]Solunum BakımıLife Sciences & BiomedicinePulmons Malalties
researchProduct